Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Onco...(hown to predict thelikelihood of breast ...),Health
| HOME >> MEDICINE >> TECHNOLOGY |
hown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, including
statements relating to the belief that the use of Oncotype DX is indicated
in treatment planning for early-stage estrogen receptor positive breast
cancer patients, the value provided by using Oncotype DX, the belief that
Oncotype DX may be clinically useful in some patients with hormone receptor
positive, node positive breast cancer, the ability of Oncotype DX to change
treatment decisions, the ability of Oncotype DX to reduce unnecessary
chemotherapy and to increase patient confidence in their treatment
decisions, the belief that Oncotype DX is becoming standard practice for
doctors and patients making treatment decisions, and Genomic Health's plans
to provide single gene reporting and the timing of any such product
enhancement. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially. These
risks and uncertainties include, but are not limited to: the applicability
of clinical results to actual outcomes; the ability of our test to continue
to impact treatment decisions; our ability to increase usage of our tests;
the risk that we may not obtain or maintain sufficient levels of
reimbursement for our existing tests and any future tests we may develop;
the risk of delay in developing new products or product enhancements; the
risks and uncertainties associated with the regulation of our test by FDA;
our ability to obtain capital when needed; our history of operating losses;
the results of clinical studies and the other risks set f
'/>"/>
| SOURCE Genomic Health, Inc. Copyright©2007 PR Newswire. All rights reserved |
Related medicine technology :
1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |